Cargando…

Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects

Background: Easyhaler(®) dry powder inhaler (DPI) containing salmeterol and fluticasone propionate was developed for the treatment of asthma and chronic obstructive pulmonary disease. Three different Salmeterol/fluticasone Easyhaler test products (Orion Pharma, Finland) were compared against the ref...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kirjavainen, Merja, Mattila, Leena, Vahteristo, Mikko, Korhonen, Jani, Lähelmä, Satu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161324/ https://www.ncbi.nlm.nih.gov/pubmed/29493402 http://dx.doi.org/10.1089/jamp.2017.1437

Ejemplares similares

In Vitro Flow Rate Dependency of Delivered Dose and Fine Particle Dose of Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus with Patient Flow Rates Collected in a Randomized Controlled Trial
por: Jõgi, Rain, et al.
Publicado: (2019)

Equivalent Lung Dose and Systemic Exposure of Budesonide/Formoterol Combination via Easyhaler and Turbuhaler
por: Lähelmä, Satu, et al.
Publicado: (2015)

Safety and Efficacy of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler Compared with Fluticasone Propionate/Salmeterol Diskus in Patients with Chronic Obstructive Pulmonary Disease
por: Koser, Andras, et al.
Publicado: (2010)

A non-interventional switch study in adult patients with asthma or COPD on clinical effectiveness of salmeterol/fluticasone Easyhaler(®) in routine clinical practice
por: Vinge, Ines, et al.
Publicado: (2021)

Consistent Dosing Through the Salmeterol–Fluticasone Propionate Easyhaler for the Management of Asthma and Chronic Obstructive Pulmonary Disease: Robustness Analysis Across the Easyhaler Lifetime
por: Turpeinen, Anni, et al.
Publicado: (2021)

Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies
por: Haughie, Scott, et al.
Publicado: (2020)

Effectiveness and Treatment Compliance of Salmeterol–Fluticasone Easyhaler(®) Among Patients with Asthma, COPD, or Asthma–COPD Overlap Syndrome: Real-World Study Findings
por: Tamási, Lilla, et al.
Publicado: (2022)

Patients with asthma or chronic obstructive pulmonary disease (COPD) can generate sufficient inspiratory flows via Easyhaler(®) dry powder inhaler: a pooled analysis of two randomized controlled trials
por: Malmberg, L. Pekka, et al.
Publicado: (2021)

Evaluation of Fluticasone Propionate and Fluticasone Propionate/Salmeterol Combination on Exercise in Pediatric and Adolescent Patients with Asthma
por: Murray, John J, et al.
Publicado: (2011)

Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma
por: Houghton, Catherine M, et al.
Publicado: (2007)

Inspiratory Flow Parameters Through Dry Powder Inhalers in Healthy Volunteers and Patients with Chronic Obstructive Pulmonary Disease (COPD): Device Resistance Does Not Limit Use in COPD
por: Jõgi, Rain, et al.
Publicado: (2021)

The comparison of fluticasone propionate/formoterol with fluticasone propionate/salmeterol for paediatric asthma: a meta-analysis of randomized controlled trials
por: Jin, Xiaofen, et al.
Publicado: (2020)

Fluticasone propionate-salmeterol versus inhaled corticosteroids plus montelukast: outcomes study in pediatric patients with asthma
por: Stanford, Richard H, et al.
Publicado: (2012)

The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD
por: Yawn, Barbara P, et al.
Publicado: (2010)

Dexamethasone/salmeterol/fluticasone-propionate: Invasive pulmonary Aspergillosis: case report
Publicado: (2021)

The efficacy and safety of fluticasone propionate/formoterol compared with fluticasone propionate/salmeterol in treating pediatric asthma: a systematic review and meta-analysis
por: Guan, Renzheng, et al.
Publicado: (2019)

Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial
por: Singh, Dave, et al.
Publicado: (2015)

Microencapsulation of Fluticasone Propionate and Salmeterol Xinafoate in Modified Chitosan Microparticles for Release Optimization
por: Ainali, Nina Maria, et al.
Publicado: (2020)

Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma
por: Pavord, Ian, et al.
Publicado: (2007)

Cost-effectiveness of combination fluticasone propionate–salmeterol 250/50 μg versus salmeterol in severe COPD patients
por: Dalal, Anand A, et al.
Publicado: (2010)

Pharmacokinetic characteristics of fluticasone, salmeterol and tiotropium after concurrent inhalation
por: Sunwoo, Jung, et al.
Publicado: (2017)

Low-dose Fluticasone Propionate in Combination With Salmeterol in Patients With Chronic Obstructive Pulmonary Disease
por: Yasui, Hideki, et al.
Publicado: (2018)

Biochemical Behaviours of Salmeterol/Fluticasone Propionate in Treating Asthma and Chronic Obstructive Pulmonary Diseases (COPD)
por: Mills, Hilla, et al.
Publicado: (2022)

Switching to the Dry-Powder Inhaler Easyhaler(®): A Narrative Review of the Evidence
por: Lavorini, Federico, et al.
Publicado: (2021)

The Diskus™: a review of its position among dry powder inhaler devices
por: Chrystyn, H
Publicado: (2007)

Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation
por: Ohar, Jill A, et al.
Publicado: (2014)

Improvement of Airflow Limitation by Fluticasone Propionate/Salmeterol in Chronic Obstructive Pulmonary Disease: What is the Specific Marker?
por: Akamatsu, Keiichiro, et al.
Publicado: (2011)

Managing moderate-to-severe paediatric asthma: a scoping review of the efficacy and safety of fluticasone propionate/salmeterol
por: Pitrez, Paulo Marcio, et al.
Publicado: (2023)

Salmeterol/fluticasone combination in the treatment of COPD
por: Chung, K F
Publicado: (2006)

Efficacy and Safety of Fluticasone Furoate/Vilanterol Compared With Fluticasone Propionate/Salmeterol Combination in Adult and Adolescent Patients With Persistent Asthma: A Randomized Trial
por: Woodcock, Ashley, et al.
Publicado: (2013)

Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma
por: Bernstein, David I, et al.
Publicado: (2011)

Step-down therapy in well-controlled asthmatic patients using salmeterol xinafoate/fluticasone propionate combination therapy
por: Horiuchi, Kazuya, et al.
Publicado: (2016)

The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD
por: Herth, Felix, et al.
Publicado: (2020)

Patients with Asthma Prescribed Once-Daily Fluticasone Furoate/Vilanterol or Twice-Daily Fluticasone Propionate/Salmeterol as Maintenance Treatment: Analysis from a Claims Database
por: Atsuta, Ryo, et al.
Publicado: (2018)

Real-life use of fluticasone propionate/salmeterol in patients with chronic obstructive pulmonary disease: a French observational study
por: Roche, Nicolas, et al.
Publicado: (2014)

Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies
por: Siler, Thomas M., et al.
Publicado: (2016)

Chinese Herbal Medicine and Salmeterol and Fluticasone Propionate for Chronic Obstructive Pulmonary Disease: Systematic Review and Network Meta-Analysis
por: Chung, Vincent C.H., et al.
Publicado: (2016)

Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy
por: Moretz, Chad, et al.
Publicado: (2020)

Novel Fluticasone Propionate and Salmeterol Fixed-Dose Combination Nano-Encapsulated Particles Using Polyamide Based on L-Lysine
por: Alyami, Mohammad H., et al.
Publicado: (2022)

Inhaled salmeterol and/or fluticasone alters structure/function in a murine model of allergic airways disease
por: Riesenfeld, Erik P, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_u6bu58e4sjfrehdub4und8vgue